Compare ASTRAZENECA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA JUBILANT LIFE SCIENCES ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 82.7 13.9 596.6% View Chart
P/BV x 23.3 1.6 1,439.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ASTRAZENECA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
JUBILANT LIFE SCIENCES
Mar-19
ASTRAZENECA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,278898 142.3%   
Low Rs883618 142.9%   
Sales per share (Unadj.) Rs228.4572.0 39.9%  
Earnings per share (Unadj.) Rs10.436.2 28.6%  
Cash flow per share (Unadj.) Rs16.359.5 27.3%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs98.8301.9 32.7%  
Shares outstanding (eoy) m25.00159.28 15.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.3 357.0%   
Avg P/E ratio x104.220.9 498.3%  
P/CF ratio (eoy) x66.412.7 521.8%  
Price / Book Value ratio x10.92.5 435.8%  
Dividend payout %012.4 0.0%   
Avg Mkt Cap Rs m27,008120,694 22.4%   
No. of employees `0001.42.4 56.7%   
Total wages/salary Rs m1,53519,260 8.0%   
Avg. sales/employee Rs Th4,210.938,120.6 11.0%   
Avg. wages/employee Rs Th1,132.28,058.4 14.1%   
Avg. net profit/employee Rs Th191.12,414.3 7.9%   
INCOME DATA
Net Sales Rs m5,71091,108 6.3%  
Other income Rs m123357 34.3%   
Total revenues Rs m5,83391,466 6.4%   
Gross profit Rs m46317,390 2.7%  
Depreciation Rs m1473,709 4.0%   
Interest Rs m02,198 0.0%   
Profit before tax Rs m43811,840 3.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,802 0.0%   
Tax Rs m1793,268 5.5%   
Profit after tax Rs m2595,770 4.5%  
Gross profit margin %8.119.1 42.5%  
Effective tax rate %40.827.6 148.0%   
Net profit margin %4.56.3 71.6%  
BALANCE SHEET DATA
Current assets Rs m3,20945,848 7.0%   
Current liabilities Rs m2,07020,897 9.9%   
Net working cap to sales %20.027.4 72.9%  
Current ratio x1.62.2 70.7%  
Inventory Days Days7257 127.4%  
Debtors Days Days3551 68.6%  
Net fixed assets Rs m79065,498 1.2%   
Share capital Rs m50159 31.4%   
"Free" reserves Rs m2,41947,930 5.0%   
Net worth Rs m2,46948,089 5.1%   
Long term debt Rs m042,429 0.0%   
Total assets Rs m4,605114,685 4.0%  
Interest coverage xNM6.4-  
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.20.8 156.1%   
Return on assets %5.66.9 81.0%  
Return on equity %10.512.0 87.4%  
Return on capital %17.712.4 142.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30012,422 2.4%   
Fx outflow Rs m2,01517,227 11.7%   
Net fx Rs m-1,715-4,805 35.7%   
CASH FLOW
From Operations Rs m8811,215 0.8%  
From Investments Rs m-94-10,118 0.9%  
From Financial Activity Rs mNA6,574 0.0%  
Net Cashflow Rs m-67,612 -0.1%  

Share Holding

Indian Promoters % 0.0 45.6 -  
Foreign collaborators % 75.0 3.5 2,142.9%  
Indian inst/Mut Fund % 0.3 8.7 3.4%  
FIIs % 15.7 21.2 74.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 21.1 43.1%  
Shareholders   12,856 23,815 54.0%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PLETHICO PHARMA  BIOCON   J.B.CHEMICALS  ALKEM LABORATORIES  AJANTA PHARMA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Telecom and Automobiles Stocks Lose(09:30 am)

Asian share markets are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.1% while the Hang Seng is down 0.1%.

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY19); Net Profit Down 166.0% (Quarterly Result Update)

May 21, 2019 | Updated on May 21, 2019

For the quarter ended March 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 1 bn (down 166.0% YoY). Sales on the other hand came in at Rs 24 bn (up 5.9% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Oct 18, 2019 12:11 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS